Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma
<p>Abstract</p> <p>Background</p> <p>Despite aggressive multimodal treatments the overall survival of patients with high-risk neuroblastoma remains poor. The aim of this study was to identify novel combination chemotherapy to improve survival rate in patients with high-...
Main Authors: | Tsang Patricia S, Cheuk Adam T, Chen Qing-Rong, Song Young K, Badgett Thomas C, Wei Jun S, Khan Javed |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/12/101 |
Similar Items
-
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
by: Karolina Borankova, et al.
Published: (2023-11-01) -
Topotecan reduces sepsis‐induced acute lung injury and decreases the inflammatory response via the inhibition of the NF‐κB signaling pathway
by: Xiaoxia Wang, et al.
Published: (2022-04-01) -
Protocol for Comprehensive Synthetic Lethality Screens
by: Damia Romero-Moya, et al.
Published: (2020-06-01) -
Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
by: Piotr J. Wysocki, et al.
Published: (2023-02-01) -
Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
by: Maria Antonietta De Ioris, et al.
Published: (2023-11-01)